IP Verse

Chemically Modified Single-Stranded Rna-Editing Oligonucleotides - EP3507366

The patent EP3507366 was granted to Proqr Therapeutics II on Oct 7, 2020. The application was originally filed on Aug 31, 2017 under application number EP17771348A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3507366

PROQR THERAPEUTICS II
Application Number
EP17771348A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Sep 4, 2020
Grant Date
Oct 7, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONJun 25, 2021MAIWALDADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONGB20170000939-
DESCRIPTIONWO2017EP65467-
DESCRIPTIONWO2016097212
INTERNATIONAL-SEARCH-REPORTWO2014011053
INTERNATIONAL-SEARCH-REPORTWO2016097212
OPPOSITIONUS8372816
OPPOSITIONUS9650627
OPPOSITIONUS9732347
OPPOSITIONWO2011085271
OPPOSITIONWO2016097212
OPPOSITIONWO2017220751

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ANGUS; SPROAT, FEBS, (19930000), vol. 325, no. 1, 2, pages 123 - 7-
DESCRIPTION- LANCASTER; KNOBLICH, Science, (20140000), vol. 345, no. 6194, page 1247125-
DESCRIPTION- MATTHEWS et al., Nat Struct Mol Biol, (20160000), vol. 23, pages 426 - 433-
DESCRIPTION- MONTIEL-GONZALEZ et al., PNAS, (20130000), vol. 110, no. 45, pages 18285 - 18290-
DESCRIPTION- SALA et al., J Surg Res., (20090000), vol. 156, no. 2, pages 205 - 212-
DESCRIPTION- SATO et al., Gastroenterology, (20110000), vol. 141, pages 1762 - 1772-
DESCRIPTION- SCHNEIDER et al., Nucleic Acids Res, (20140000), vol. 42, no. 10, page e87-
DESCRIPTION- SHARMA; WATTS, Future Med. Chem., (20150000), vol. 7, no. 16, pages 2221 - 2242-
DESCRIPTION- STEFL et al., Structure, (20060000), vol. 14, no. 2, pages 345 - 355-
DESCRIPTION- TIAN et al., Nucleic Acids Res, (20110000), vol. 39, no. 13, pages 5669 - 5681-
DESCRIPTION- VOGEL et al., Angewandte Chemie Int Ed, (20140000), vol. 53, pages 267 - 271-
DESCRIPTION- WOOLF et al., Proc Natl Acad Sci USA, (19950000), vol. 92, pages 8298 - 8302-
INTERNATIONAL-SEARCH-REPORT- M. F. MONTIEL-GONZALEZ ET AL, "Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES, US, (20131009), vol. 110, no. 45, doi:10.1073/pnas.1306243110, ISSN 0027-8424, pages 18285 - 18290, XP055404008 [AD] 1-19 * the whole document *
INTERNATIONAL-SEARCH-REPORT- WOOLF T M ET AL, "TOWARD THE THERAPEUTIC EDITING OF MUTATED RNA SEQUENCES", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES, (19950801), vol. 92, doi:10.1073/PNAS.92.18.8298, ISSN 0027-8424, pages 8298 - 8302, XP000574995 [AD] 1-19 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MARIA FERNANDA MONTIEL-GONZÁLEZ ET AL, "An efficient system for selectively altering genetic information within mRNAs", NUCLEIC ACIDS RESEARCH, GB, (20160823), vol. 44, doi:10.1093/nar/gkw738, ISSN 0305-1048, page e157, XP055404024 [A] 1-19 * the whole document *
INTERNATIONAL-SEARCH-REPORT- VIVEK K SHARMA ET AL, "Oligonucleotide therapeutics: chemistry, delivery and clinical progress", FUTURE MEDICINAL CHEMISTRY, GB, (20151001), vol. 7, no. 16, doi:10.4155/fmc.15.144, ISSN 1756-8919, pages 2221 - 2242, XP055428414 [AD] 1-14 * the whole document *
OPPOSITION- Macbeth, Et Al., "Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding", RNA, (20040101), vol. 10, pages 1563 - 1571, XP055800800-
OPPOSITION- VOGEL P.; SCHNEIDER M.F.; WETTENGEL J.; STAFFORST T., "Improving site-directed RNA editing in vitro and in cell culture by chemical modification ofthe guideRNA", ANGEWANDTE CHEMIE, (20140101), vol. 53, pages 6267 - 6271, XP002765255-
OPPOSITION- WOOLF T. M., CHASE J. M., STINCHCOMB D. T., "TOWARD THE THERAPEUTIC EDITING OF MUTATED RNA SEQUENCES.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19950801), vol. 92., doi:10.1073/pnas.92.18.8298, ISSN 0027-8424, pages 8298 - 8302., XP000574995
OPPOSITION- Yiannis A Savva, Leila E. Rieder, Robert A. Reenan, "The ADAR protein family", Genome Biology, BioMed Central Ltd., (20120101), vol. 13, no. 12, doi:10.1186/gb-2012-13-12-252, ISSN 1465-6906, page 252, XP093159128

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents